Palisade Bio Reports $14.6 Million Q3 Net Loss and Advances PALI-2108 Trials

Palisade Bio reported a third-quarter 2026 net loss of $14.6 million, or $0.07 per share, compared with a $2.9 million loss a year earlier. The company ended September with $113.6 million in cash and cash equivalents. It also reported progress in its Phase 2 programs for PALI-2108, including dosing…